Appeal No. 2004-0600 Paper 16
Application No. 10/024,983 Page 5
13. We make reference to (a) the Office action finally rejecting claims 7-12 ("Final
Rejection"), Paper 8, mailed October 1, 2002, (b) the Examiner's Answer ("Answer"),
Paper 11, mailed December 31, 2002, and (c) Appellant's Brief Under 37 CFR
§ 1.192(a) ("Brief"), Paper 10, filed October 15, 2002.
14. The examiner relies on the following references as evidence of obviousness:
Schilling, Jr. et al. (Schilling) 4,150,048 April 17, 1979
Schulz, Jr. et al. (Schulz) 5,654,362 August 5, 1997
Zhang 5,889,108 March 30, 1999
Lin et al. (Lin) 6,207,717 March 27, 2001
REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed., A. Gennaro et al.
(eds.), 1990, p. 1314 (Remington).
Other findings of fact follow below.
B. Issues
1. the rejection
15. The examiner has rejected claims 7-12 under 35 U.S.C. § 103(a) as being
obvious over Lin in view of Schilling, Schulz, Remington and Zhang (Final Rejection, p.
2; Answer, p. 3).
16. As a preliminary matter, we note that claims 7-12 stand or fall together with
respect to the rejection under 35 U.S.C. § 103 (brief, page 3). Thus, we direct our
attention to claim 7. See 37 C.F.R. § 1.192(c)(5)(1993).
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007